Sudeep Pharma's IPO proved profitable for investors. The issue price was ₹593, while it traded at ₹730 upon listing. As a result, investors made an immediate profit of ₹137 or 23.10% per share.
IPO Update: Sudeep Pharma's IPO performed exceptionally well in the grey market. Prior to listing, its GMP (Grey Market Premium) was recorded at ₹121, leading to tremendous enthusiasm among investors for its shares. Following allotment, investors made significant investments, and the company lived up to their expectations. On the listing day, November 26, at 8:30 AM, its GMP and share price delighted investors.
Profit on Listing Day
Sudeep Pharma's issue price was ₹593 per share, while it traded at ₹730 at the time of listing. This resulted in an immediate profit of ₹137 or 23.10 percent per share for investors. This IPO proved to be quite attractive to investors and saw increased demand in the market.
Company's Financial Performance
Sudeep Pharma's financial performance has consistently been b. As of June 2025, the company's revenue was ₹124.9 crore and profit after tax was ₹31.3 crore. In fiscal year 2024-25, revenue stood at ₹502 crore and profit at ₹138.7 crore. Prior to this, in fiscal years 2023-24 and 2022-23, the company also showed consistent growth in profit, thereby increasing investor confidence.
Basic IPO Information
Sudeep Pharma's price band was ₹563 to ₹593. The lot size was 25 equity shares, and the face value was ₹1. Under the fresh issue, 95 lakh shares were issued, and the Offer For Sale included 13,490,726 shares. The IPO opened on November 21 and closed on November 25, 2025.
What the Company Does
Sudeep Pharma was established in 1989. It manufactures pharmaceutical and nutritional food products. The company has over 100 products available in the market and also has an international presence. Sudeep Pharma operates in approximately 100 countries, with the USA, Europe, and the UK being prominent.
